U.S., April 21 -- ClinicalTrials.gov registry received information related to the study (NCT07539285) titled 'A Study of HDM2024 in Participants With Advanced Solid Tumors' on March 27.
Brief Summary: The goal of this clinical trial is to learn if the study drug can work in advanced cancer patients. The main questions it aims to answer are:
* Is the drug safe and tolerable ?
* Does the drug exhibit antitumor activity ?
Participants will receive the study drug once every three weeks, and imaging-based efficacy assessments will be performed every six weeks.
Study Start Date: April 10
Study Type: INTERVENTIONAL
Condition:
Advanced Solid Tumors
Intervention:
DRUG: HDM2024
ADC drug targeting EGFR and HER3
Recruitment Status: RECRUITI...